Published in Proc Natl Acad Sci U S A on January 03, 2006
Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression. Proc Natl Acad Sci U S A (2008) 5.24
The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies. Brain Res Rev (2008) 2.39
Deletion of tumor necrosis factor death receptor inhibits amyloid beta generation and prevents learning and memory deficits in Alzheimer's mice. J Cell Biol (2007) 1.90
Glial cells in (patho)physiology. J Neurochem (2012) 1.89
Docosahexaenoic acid signalolipidomics in nutrition: significance in aging, neuroinflammation, macular degeneration, Alzheimer's, and other neurodegenerative diseases. Annu Rev Nutr (2011) 1.88
The Alzheimer's disease beta-secretase enzyme, BACE1. Mol Neurodegener (2007) 1.81
Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. Proc Natl Acad Sci U S A (2009) 1.76
Neuroinflammatory processes in Alzheimer's disease. J Neural Transm (Vienna) (2010) 1.73
The role of amyloid precursor protein processing by BACE1, the beta-secretase, in Alzheimer disease pathophysiology. J Biol Chem (2008) 1.57
Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res (2008) 1.56
Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci (2007) 1.48
Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase- and PPARγ-mediated mechanisms in Alzheimer's disease models. PLoS One (2011) 1.45
MicroRNA-27b contributes to lipopolysaccharide-mediated peroxisome proliferator-activated receptor gamma (PPARgamma) mRNA destabilization. J Biol Chem (2010) 1.44
High cholesterol-induced neuroinflammation and amyloid precursor protein processing correlate with loss of working memory in mice. J Neurochem (2008) 1.41
PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics (2008) 1.36
Aging is associated with an increase in T cells and inflammatory macrophages in visceral adipose tissue. J Immunol (2011) 1.35
Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience (2006) 1.31
The comorbidity of HIV-associated neurocognitive disorders and Alzheimer's disease: a foreseeable medical challenge in post-HAART era. J Neuroimmune Pharmacol (2008) 1.31
Oxidative stress and transcriptional regulation in Alzheimer disease. Alzheimer Dis Assoc Disord (2007) 1.29
NSAIDs prevent, but do not reverse, neuronal cell cycle reentry in a mouse model of Alzheimer disease. J Clin Invest (2009) 1.23
Microglia activation and anti-inflammatory regulation in Alzheimer's disease. Mol Neurobiol (2010) 1.22
TREM2 and the neuroimmunology of Alzheimer's disease. Biochem Pharmacol (2013) 1.18
Why pleiotropic interventions are needed for Alzheimer's disease. Mol Neurobiol (2010) 1.18
Microglia function in Alzheimer's disease. Front Pharmacol (2012) 1.17
Interactions between APP secretases and inflammatory mediators. J Neuroinflammation (2008) 1.14
Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology. Neuropsychopharmacology (2010) 1.12
BACE1 is at the crossroad of a toxic vicious cycle involving cellular stress and β-amyloid production in Alzheimer's disease. Mol Neurodegener (2012) 1.11
Inflammatory process in Alzheimer's Disease. Front Integr Neurosci (2013) 1.10
Differential regulation of BACE1 expression by oxidative and nitrosative signals. Mol Neurodegener (2011) 1.06
Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of Alzheimer's disease. J Alzheimers Dis (2012) 1.03
SCFFbx2-E3-ligase-mediated degradation of BACE1 attenuates Alzheimer's disease amyloidosis and improves synaptic function. Aging Cell (2010) 1.02
Nuclear receptors and inflammatory diseases. Exp Biol Med (Maywood) (2008) 1.01
Leptin attenuates BACE1 expression and amyloid-β genesis via the activation of SIRT1 signaling pathway. Biochim Biophys Acta (2014) 1.00
Possible mechanisms of action of NSAIDs and related compounds that modulate gamma-secretase cleavage. Curr Top Med Chem (2008) 0.99
Modulation of inflammation in transgenic models of Alzheimer's disease. J Neuroinflammation (2014) 0.99
Are NSAIDs useful to treat Alzheimer's disease or mild cognitive impairment? Front Aging Neurosci (2010) 0.98
Metabolic stress modulates Alzheimer's β-secretase gene transcription via SIRT1-PPARγ-PGC-1 in neurons. Cell Metab (2013) 0.98
Inhibitory effect of 4-O-methylhonokiol on lipopolysaccharide-induced neuroinflammation, amyloidogenesis and memory impairment via inhibition of nuclear factor-kappaB in vitro and in vivo models. J Neuroinflammation (2012) 0.96
Depletion of GGA1 and GGA3 mediates postinjury elevation of BACE1. J Neurosci (2012) 0.95
Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease. Acta Neuropathol (2012) 0.95
The Nuclear Receptor PPARgamma as a Therapeutic Target for Cerebrovascular and Brain Dysfunction in Alzheimer's Disease. Front Aging Neurosci (2010) 0.93
Beta-secretase: structure, function, and evolution. CNS Neurol Disord Drug Targets (2008) 0.92
Synaptic and cognitive improvements by inhibition of 2-AG metabolism are through upregulation of microRNA-188-3p in a mouse model of Alzheimer's disease. J Neurosci (2014) 0.91
Modulation of microglial innate immunity in Alzheimer's disease by activation of peroxisome proliferator-activated receptor gamma. Curr Med Chem (2009) 0.90
The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimer's Disease. Curr Genomics (2007) 0.90
Signaling effect of amyloid-beta(42) on the processing of AbetaPP. Exp Neurol (2009) 0.89
Decrease in the production of β-amyloid by berberine inhibition of the expression of β-secretase in HEK293 cells. BMC Neurosci (2011) 0.89
β-Secretase: its biology as a therapeutic target in diseases. Trends Pharmacol Sci (2013) 0.88
Activation of TRPML1 clears intraneuronal Aβ in preclinical models of HIV infection. J Neurosci (2014) 0.88
NSAIDs: How they Work and their Prospects as Therapeutics in Alzheimer's Disease. Front Aging Neurosci (2010) 0.86
Exploring the contribution of estrogen to amyloid-Beta regulation: a novel multifactorial computational modeling approach. Front Pharmacol (2013) 0.86
Tracking neuroinflammation in Alzheimer's disease: the role of positron emission tomography imaging. J Neuroinflammation (2014) 0.85
Nuclear receptors in neurodegenerative diseases. Neurobiol Dis (2014) 0.85
Deficiency of Neuronal p38α MAPK Attenuates Amyloid Pathology in Alzheimer Disease Mouse and Cell Models through Facilitating Lysosomal Degradation of BACE1. J Biol Chem (2015) 0.84
Potential Therapeutic Targets for PPARgamma after Spinal Cord Injury. PPAR Res (2008) 0.84
Sulindac derivatives that activate the peroxisome proliferator-activated receptor gamma but lack cyclooxygenase inhibition. J Med Chem (2008) 0.84
Diet and age interactions with regards to cholesterol regulation and brain pathogenesis. Curr Gerontol Geriatr Res (2010) 0.83
Effects of long-term treatment with pioglitazone on cognition and glucose metabolism of PS1-KI, 3xTg-AD, and wild-type mice. Cell Death Dis (2012) 0.83
AlzPlatform: an Alzheimer's disease domain-specific chemogenomics knowledgebase for polypharmacology and target identification research. J Chem Inf Model (2014) 0.82
Inhibition of amyloidogenesis by nonsteroidal anti-inflammatory drugs and their hybrid nitrates. J Med Chem (2011) 0.82
PPARγ2 polymorphism and human health. PPAR Res (2009) 0.82
The Role of PPAR Ligands in Controlling Growth-Related Gene Expression and their Interaction with Lipoperoxidation Products. PPAR Res (2008) 0.81
Short-term treatment with tolfenamic acid improves cognitive functions in Alzheimer's disease mice. Neurobiol Aging (2013) 0.80
Mechanisms of peroxisome proliferator activated receptor γ regulation by non-steroidal anti-inflammatory drugs. Nucl Recept Signal (2015) 0.80
Alzheimer's Disease: Fatty Acids We Eat may be Linked to a Specific Protection via Low-dose Aspirin. Aging Dis (2010) 0.79
Combined Liver X Receptor/Peroxisome Proliferator-activated Receptor γ Agonist Treatment Reduces Amyloid β Levels and Improves Behavior in Amyloid Precursor Protein/Presenilin 1 Mice. J Biol Chem (2015) 0.79
Influence of drug transporters and stereoselectivity on the brain penetration of pioglitazone as a potential medicine against Alzheimer's disease. Sci Rep (2015) 0.79
Staging anti-inflammatory therapy in Alzheimer's disease. Front Aging Neurosci (2010) 0.79
NSAIDs in the treatment and/or prevention of neurological disorders. Inflammopharmacology (2012) 0.79
Presenilin/gamma-Secretase and Inflammation. Front Aging Neurosci (2010) 0.79
Pilot data on telmisartan short-term effects on glucose metabolism in the olfactory tract in Alzheimer's disease. Brain Behav (2011) 0.79
Transcriptional regulation and its misregulation in Alzheimer's disease. Mol Brain (2013) 0.79
The normal and pathologic roles of the Alzheimer's β-secretase, BACE1. Curr Alzheimer Res (2014) 0.78
Colon-targeted delivery of live bacterial cell biotherapeutics including microencapsulated live bacterial cells. Biologics (2008) 0.78
PPARγ-coactivator-1α gene transfer reduces neuronal loss and amyloid-β generation by reducing β-secretase in an Alzheimer's disease model. Proc Natl Acad Sci U S A (2016) 0.78
Current pharmacotherapy and putative disease-modifying therapy for Alzheimer's disease. Neurol Sci (2016) 0.77
Role of LDL cholesterol and endolysosomes in amyloidogenesis and Alzheimer's disease. J Neurol Neurophysiol (2014) 0.77
CHIP stabilizes amyloid precursor protein via proteasomal degradation and p53-mediated trans-repression of β-secretase. Aging Cell (2015) 0.77
The anti-inflammatory Annexin A1 induces the clearance and degradation of the amyloid-β peptide. J Neuroinflammation (2016) 0.76
Pan-PPAR modulation effectively protects APP/PS1 mice from amyloid deposition and cognitive deficits. Mol Neurobiol (2014) 0.76
Astragaloside IV, a Natural PPARγ Agonist, Reduces Aβ Production in Alzheimer's Disease Through Inhibition of BACE1. Mol Neurobiol (2016) 0.76
Effects of conjugated linoleic acid on cleavage of amyloid precursor protein via PPARγ. Neurol Sci (2011) 0.76
An overview on therapeutics attenuating amyloid β level in Alzheimer's disease: targeting neurotransmission, inflammation, oxidative stress and enhanced cholesterol levels. Am J Transl Res (2016) 0.76
Two novel DNA motifs are essential for BACE1 gene transcription. Sci Rep (2014) 0.76
Neuroinflammation is not a Prerequisite for Diabetes-induced Tau Phosphorylation. Front Neurosci (2015) 0.76
Lack of Genetic Associations of PPAR-γ and PGC-1α with Alzheimer's Disease and Parkinson's Disease with Dementia. Dement Geriatr Cogn Dis Extra (2013) 0.75
Differential peroxisome proliferator activated receptors activity in a rodent model of amyotrophic lateral sclerosis. Int J Clin Exp Med (2015) 0.75
All-trans-retinoic acid reduces BACE1 expression under inflammatory conditions via modulation of nuclear factor κB (NFκB) signaling. J Biol Chem (2015) 0.75
α-Synuclein increases β-amyloid secretion by promoting β-/γ-secretase processing of APP. PLoS One (2017) 0.75
Neuronally-directed effects of RXR activation in a mouse model of Alzheimer's disease. Sci Rep (2017) 0.75
Cytokines and Cytokine Receptors Involved in the Pathogenesis of Alzheimer's Disease. J Clin Cell Immunol (2016) 0.75
Early Growth Response 1 (Egr-1) Is a Transcriptional Activator of β-Secretase 1 (BACE-1) in the Brain. J Biol Chem (2016) 0.75
Therapeutic potential of nuclear receptor agonists in Alzheimer's disease. J Lipid Res (2017) 0.75
Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell (1994) 17.58
Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science (1999) 13.19
Inflammation and Alzheimer's disease. Neurobiol Aging (2000) 12.56
Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med (2001) 7.85
A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature (2001) 7.35
Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A (1994) 6.46
C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway. Genes Dev (2002) 6.46
Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest (2000) 5.07
Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci (2000) 4.14
The mouse peroxisome proliferator activated receptor recognizes a response element in the 5' flanking sequence of the rat acyl CoA oxidase gene. EMBO J (1992) 3.92
Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem (1997) 3.55
NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest (2003) 3.50
Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. Ann Neurol (2002) 3.30
BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. Neuron (2004) 2.90
Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. Proc Natl Acad Sci U S A (2004) 2.88
Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology (2004) 2.63
Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain (2005) 2.27
Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci (2003) 2.27
Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation. Nat Med (2004) 1.91
Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol Pharmacol (1996) 1.90
Oxidative stress increases expression and activity of BACE in NT2 neurons. Neurobiol Dis (2002) 1.85
Transcriptional regulation of BACE1, the beta-amyloid precursor protein beta-secretase, by Sp1. Mol Cell Biol (2004) 1.70
Beta-secretase activity increases with aging in human, monkey, and mouse brain. Am J Pathol (2004) 1.70
Gene structure and organization of the human beta-secretase (BACE) promoter. FASEB J (2004) 1.56
Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci (2003) 1.56
Experimental traumatic brain injury in rats stimulates the expression, production and activity of Alzheimer's disease beta-secretase (BACE-1). J Neural Transm (Vienna) (2004) 1.47
Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer's disease. Am J Pathol (2004) 1.47
TNF alpha-mediated inhibition and reversal of adipocyte differentiation is accompanied by suppressed expression of PPARgamma without effects on Pref-1 expression. Endocrinology (1997) 1.30
Differential utilization of upstream AUGs in the beta-secretase mRNA suggests that a shunting mechanism regulates translation. Proc Natl Acad Sci U S A (2004) 1.26
Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J Neurosci (2000) 1.25
BACE1 (beta-secretase) knockout mice do not acquire compensatory gene expression changes or develop neural lesions over time. Neurobiol Dis (2003) 1.20
Astrocytic expression of the Alzheimer's disease beta-secretase (BACE1) is stimulus-dependent. Glia (2003) 1.19
Peroxisome-proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide. J Neurosci (2004) 1.14
Ibuprofen decreases cytokine-induced amyloid beta production in neuronal cells. Neurobiol Dis (2001) 0.98
Plasma and cerebrospinal fluid concentrations of indomethacin in humans. Relationship to analgesic activity. Eur J Clin Pharmacol (1990) 0.94
Activation of peroxisome proliferator-activated receptor isoforms and inhibition of prostaglandin H(2) synthases by ibuprofen, naproxen, and indomethacin. Biochem Pharmacol (2001) 0.93
Cloning and expression of the rat BACE1 promoter. J Neurosci Res (2003) 0.91
Stereoselective disposition of ibuprofen enantiomers in human cerebrospinal fluid. Br J Clin Pharmacol (1995) 0.89
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol (2014) 3.75
Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol (2011) 3.69
Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum Mol Genet (2005) 3.45
A Toll-like receptor 2 ligand stimulates Th2 responses in vivo, via induction of extracellular signal-regulated kinase mitogen-activated protein kinase and c-Fos in dendritic cells. J Immunol (2004) 3.25
The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol (2013) 2.65
A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J Clin Invest (2004) 2.52
ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. EMBO J (2010) 2.35
Distinct and non-redundant roles of microglia and myeloid subsets in mouse models of Alzheimer's disease. J Neurosci (2011) 2.31
Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain (2005) 2.27
Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci (2003) 2.27
Microglial phagocytosis of fibrillar beta-amyloid through a beta1 integrin-dependent mechanism. J Neurosci (2004) 2.24
Biological and clinical characteristics of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 in the longitudinal RISCA study: analysis of baseline data. Lancet Neurol (2013) 2.24
Deletion of the transient receptor potential cation channel TRPV4 impairs murine bladder voiding. J Clin Invest (2007) 2.19
Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine. Proc Natl Acad Sci U S A (2010) 2.15
Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol (2003) 2.14
PPARγ/RXRα-induced and CD36-mediated microglial amyloid-β phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice. J Neurosci (2012) 2.12
Progressive cognitive dysfunction in spinocerebellar ataxia type 3. Mov Disord (2013) 2.09
Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol (2004) 2.08
Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. Neurology (2012) 2.02
Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology. Nat Med (2008) 2.01
Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice. Proc Natl Acad Sci U S A (2004) 2.00
Presenilin-dependent intramembrane proteolysis of CD44 leads to the liberation of its intracellular domain and the secretion of an Abeta-like peptide. J Biol Chem (2002) 1.97
Mutations in ABHD12 cause the neurodegenerative disease PHARC: An inborn error of endocannabinoid metabolism. Am J Hum Genet (2010) 1.95
The nuclear receptor PPAR gamma selectively inhibits Th17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmunity. J Exp Med (2009) 1.95
Glucose metabolism, gray matter structure, and memory decline in subjective memory impairment. Neurology (2012) 1.94
Mutant valosin-containing protein causes a novel type of frontotemporal dementia. Ann Neurol (2005) 1.94
Glial cells in (patho)physiology. J Neurochem (2012) 1.89
Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease. Nature (2011) 1.87
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement (2011) 1.87
Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann Neurol (2002) 1.86
Staging of neurofibrillary pathology in Alzheimer's disease: a study of the BrainNet Europe Consortium. Brain Pathol (2008) 1.85
Red flags for multiple system atrophy. Mov Disord (2008) 1.75
A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease. Arch Neurol (2010) 1.73
Neuropsychological features of patients with spinocerebellar ataxia (SCA) types 1, 2, 3, and 6. Cerebellum (2010) 1.69
Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov Disord (2003) 1.69
Pathological consequences of VCP mutations on human striated muscle. Brain (2006) 1.68
Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms. Int J Dev Neurosci (2006) 1.68
Amyloid activates GSK-3beta to aggravate neuronal tauopathy in bigenic mice. Am J Pathol (2008) 1.65
Serial MRI of limbic encephalitis. Neuroradiology (2006) 1.63
Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J Neurochem (2004) 1.61
Systemic inflammation induces apoptosis with variable vulnerability of different brain regions. J Chem Neuroanat (2005) 1.61
Fibrillar beta-amyloid-stimulated intracellular signaling cascades require Vav for induction of respiratory burst and phagocytosis in monocytes and microglia. J Biol Chem (2006) 1.59
Reliability and validity of the scale for the assessment and rating of ataxia: a study in 64 ataxia patients. Mov Disord (2007) 1.58
Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci (2003) 1.56
Interlaboratory comparison of assessments of Alzheimer disease-related lesions: a study of the BrainNet Europe Consortium. J Neuropathol Exp Neurol (2006) 1.56
The capsaicin receptor TRPV1 is a crucial mediator of the noxious effects of mustard oil. Curr Biol (2011) 1.56
Tumor detection with 5-aminolevulinic acid fluorescence and Gd-DTPA-enhanced intraoperative MRI at the border of contrast-enhancing lesions: a prospective study based on histopathological assessment. Neurosurg Focus (2014) 1.54
A pan-European study of the C9orf72 repeat associated with FTLD: geographic prevalence, genomic instability, and intermediate repeats. Hum Mutat (2013) 1.53
The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo. Clin Cancer Res (2003) 1.53
Mechanisms of statin-mediated inhibition of small G-protein function. J Biol Chem (2005) 1.52
Management of a twenty-first century brain bank: experience in the BrainNet Europe consortium. Acta Neuropathol (2008) 1.51
Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer's disease. J Lipid Res (2003) 1.50
Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG). Mov Disord (2006) 1.49
In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate. Ann Neurol (2006) 1.48
L1 endocytosis is controlled by a phosphorylation-dephosphorylation cycle stimulated by outside-in signaling by L1. J Cell Biol (2002) 1.47
The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J Neurosci (2005) 1.47
BRI2 protein regulates β-amyloid degradation by increasing levels of secreted insulin-degrading enzyme (IDE). J Biol Chem (2011) 1.47
GGA proteins regulate retrograde transport of BACE1 from endosomes to the trans-Golgi network. Mol Cell Neurosci (2005) 1.47
Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J Neurosci (2006) 1.46
Sepsis causes neuroinflammation and concomitant decrease of cerebral metabolism. J Neuroinflammation (2008) 1.46
Noradrenergic depletion potentiates beta -amyloid-induced cortical inflammation: implications for Alzheimer's disease. J Neurosci (2002) 1.46
Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease. Acta Neuropathol (2010) 1.46
Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord (2010) 1.45
An arginine/lysine-rich motif is crucial for VCP/p97-mediated modulation of ataxin-3 fibrillogenesis. EMBO J (2006) 1.45
Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice. J Neuroinflammation (2005) 1.45
Microglial repopulation model reveals a robust homeostatic process for replacing CNS myeloid cells. Proc Natl Acad Sci U S A (2012) 1.43
Nitration of tyrosine 10 critically enhances amyloid β aggregation and plaque formation. Neuron (2011) 1.42
Improved long-term potentiation and memory in young tau-P301L transgenic mice before onset of hyperphosphorylation and tauopathy. J Neurosci (2006) 1.41